Skip to main content
SpringerLink
Log in

RETRACTED ARTICLE: Aplysin enhances temozolomide sensitivity in glioma cells by increasing miR-181 level

  • Original Article
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

This article was retracted on 26 October 2020

This article has been updated

Abstract

Purpose

Aplysin, a natural brominate compound from marine organisms, has been demonstrated to exhibit anti-tumor activity, mainly by inducing apoptosis and cell cycle arrest. However, its effect on glioma is still unknown. In this study, we evaluated the effects of aplysin on the malignant properties of glioma cells and its enhancing effect on temozolomide (TMZ) action against drug-resistant glioma cell lines.

Methods

We employed several human glioma cell lines and primary glioma cells to address this issue with multidisciplinary approaches.

Results

The combined application of aplysin and TMZ significantly sensitizes glioma cells to TMZ action, compared with TMZ alone. miRNA profile analysis revealed that the abundance of miR-181, an important glioma tumor suppressors believed to enhance TMZ effect, was greatly elevated in aplysin-treated glioma cell lines. The aplysin-induced TMZ sensitivity is dependent on MEK1 in glioma cells. Overexpression of MEK1 was able to abolish the effect of aplysin on glioma cells.

Conclusions

We found that aplysin can enhance the effect of TMZ on glioma cells by increasing miR-181 expression.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

Change history

References

  1. Reardon DA, Galanis E, DeGroot JF, Cloughesy TF, Wefel JS, Lamborn KR, Lassman AB, Gilbert MR, Sampson JH, Wick W, Chamberlain MC, Macdonald DR, Mehta MP, Vogelbaum MA, Chang SM, Van den Bent MJ, Wen PY (2011) Clinical trial end points for high-grade glioma: the evolving landscape. Neuro Oncol 13(3):353–361. doi:10.1093/neuonc/noq203

    Article  PubMed  PubMed Central  Google Scholar 

  2. Chang L, Su J, Jia X, Ren H (2014) Treating malignant glioma in Chinese patients: update on temozolomide. Onco Targets Ther 7:235–244. doi:10.2147/OTT.S41336

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Johannessen TC, Bjerkvig R (2012) Molecular mechanisms of temozolomide resistance in glioblastoma multiforme. Expert Rev Anticancer Ther 12(5):635–642. doi:10.1586/era.12.37

    Article  CAS  PubMed  Google Scholar 

  4. Wang J, Sai K, Chen FR, Chen ZP (2013) miR-181b modulates glioma cell sensitivity to temozolomide by targeting MEK1. Cancer Chemother Pharmacol 72(1):147–158. doi:10.1007/s00280-013-2180-3

    Article  CAS  PubMed  Google Scholar 

  5. Ge N, Liang H, Liu Y, Ma AG, Han L (2013) Protective effect of Aplysin on hepatic injury in ethanol-treated rats. Food Chemical Toxicol 62:361–372. doi:10.1016/j.fct.2013.08.071

    Article  CAS  Google Scholar 

  6. Liang H, Liu Y, Ge N, Ma AG (2013) Effects of aplysin on the apoptosis of human breast can FCM-7 cell. Ann Nutr Metab 63:1660

    Google Scholar 

  7. Tian X, Tang H, Lin H, Cheng G, Wang S, Zhang X (2013) Saponins: the potential chemotherapeutic agents in pursuing new anti-glioblastoma drugs. Min Rev Med Chem 13(12):1709–1724

    Article  CAS  Google Scholar 

  8. Shi L, Cheng Z, Zhang J, Li R, Zhao P, Fu Z, You Y (2008) hsa-mir-181a and hsa-mir-181b function as tumor suppressors in human glioma cells. Brain Res 1236:185–193. doi:10.1016/j.brainres.2008.07.085

    Article  CAS  PubMed  Google Scholar 

  9. Chen G, Zhu W, Shi D, Lv L, Zhang C, Liu P, Hu W (2010) MicroRNA-181a sensitizes human malignant glioma U87MG cells to radiation by targeting Bcl-2. Oncol Rep 23(4):997–1003

    CAS  PubMed  Google Scholar 

  10. Kouri FM, Jensen SA, Stegh AH (2012) The role of Bcl-2 family proteins in therapy responses of malignant astrocytic gliomas: Bcl2L12 and beyond. ScientificWorldJournal 2012:838916. doi:10.1100/2012/838916

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Hummel TR, Chow LM, Fouladi M, Franz D (2013) Pharmacotherapeutic management of pediatric gliomas : current and upcoming strategies. Paediatr Drugs 15(1):29–42. doi:10.1007/s40272-012-0002-4

    Article  PubMed  Google Scholar 

  12. Nakada M, Furuta T, Hayashi Y, Minamoto T, Hamada J (2012) The strategy for enhancing temozolomide against malignant glioma. Front Oncol 2:98. doi:10.3389/fonc.2012.00098

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Holt SV, Logie A, Odedra R, Heier A, Heaton SP, Alferez D, Davies BR, Wilkinson RW, Smith PD (2012) The MEK1/2 inhibitor, selumetinib (AZD6244; ARRY-142886), enhances anti-tumour efficacy when combined with conventional chemotherapeutic agents in human tumour xenograft models. Br J Cancer 106(5):858–866. doi:10.1038/bjc.2012.8

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Conflict of interest

None.

Author information

Authors and Affiliations

  1. Department of Neurosurgery, The Affiliated Hospital of Qingdao University, Qingdao, 266003, China

    Anjing Gong, Weicheng Yao & Luxiang Lu

  2. The Institute of Human Nutrition, Medical College of Qingdao University, 38 Dengzhou Road, Qingdao, 266021, China

    Na Ge & Hui Liang

Authors
  1. Anjing Gong
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Na Ge
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Weicheng Yao
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Luxiang Lu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Hui Liang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hui Liang.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Gong, A., Ge, N., Yao, W. et al. RETRACTED ARTICLE: Aplysin enhances temozolomide sensitivity in glioma cells by increasing miR-181 level. Cancer Chemother Pharmacol 74, 531–538 (2014). https://doi.org/10.1007/s00280-014-2534-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00280-014-2534-5

Keywords

Search

Navigation